RXi licences ovarian cancer vax

Worcester, MA-based RXi Pharmaceuticals has licensed an ovarian cancer vaccine from The University of Texas MD Anderson Cancer Center and Henry M. Jackson Foundation for the Advancement of Military Medicine. The vaccine, which is designed to prevent the recurrence of endometrial adenocarcinomas, as well as ovarian and other gynecological cancers, targets folate binding protein-E39. FBP is overexpressed in ovarian and aggressive endometrial cancers, as well as breast, lung, colorectal and renal cell carcinomas. Phase I trials will begin later this year. Release